Evidence map›Paper›PMID 19384553›Full record

ReviewZeitschrift fur Rheumatologie2009

[From stem cells to lymphocytes].

F Melchers

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The future of disease prevention.Medical hypotheses · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

F MelchersMax-Planck-Institut für Infektionsbiologie, Senior Research Group Lymphozytenentwicklung, Charité-Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Deutschland. melchers@mpiib-berlin.mpg.de
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two types of pluripotent stem cells form the origins of the cells of the innate and the adaptive immune system, as well as of essential elements of cooperating environments of this system. Pluripotent hematopoietic stem cells and their subordinated, sub-specialized progenitor cells develop, throughout life, the red cells, platelets, myeloid and lymphoid cells of this continuously regenerating cell system. Pluripotent mesenchymal cells generate, among other types of differentiated cells, chondrocytes, epithelial cells, adipocytes and osteoblasts. These osteoblasts not only produce bone, the primary location for the hematopoietic cell development, but also directly interact with the hematopoietic stem and progenitor cells - and also with the mature, antigen-experienced memory types of lymphocytes which return after successful fights with antigens to the place of their origin. These interactions occur both by cell-cell contacts and cytokine-cytokine receptor recognitions in so-called"niches", and induce and guide the developments of the hematopoietic cells. These early phases of hematopoietic development are antigen-independent, because the cells of the adaptive system, the lymphocytes, have not yet made antigen-specific receptors. As soon as these cells express T-cell and B-cell receptors for antigen they are subjected to negative and positive selection pressures, first by auto-antigens in the primary lymphoid organs, then after maturation and migration to secondary lymphoid organs, also to external, foreign antigens. The repertoires of these lymphocytes expressing TcR and BcR adapt to the body's own, as well as external environmental, antigens. While cell-cell contacts with cooperating non-hematopoietic as well as hematopoietic cells, and cytokine-cytokine receptor interactions continue to induce the cellular responses resulting in proliferation, differentiation and/or programmed cell death (apoptosis) of the mature hematopoietic cells, such responses of lymphocytes are now dominated by the specific interactions of their antigen-specific receptors, TcRs or BrCs with antigens.

Indexed as

AnimalsAutoantigensB-LymphocytesCell DifferentiationEpitopesHumansImmunity, ActiveImmunity, InnateLymphocytesMicePluripotent Stem CellsT-LymphocytesAutoantigensEpitopes

Identifiers

PMID19384553
OpenAlexW109298869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.